# Nilo funding rounds and investors

As of 8 Nov 2026, Nilo has raised $101M across 1 verified round on record; latest: $101M Series A led by DCVC Bio, Lux Capital and 1 other, announced 8 Oct 2025.

Nilo Therapeutics develops medicines that target neural circuits to restore immune balance in autoimmune and inflammatory disease.

Website: https://www.nilotx.com  
Headquarters: New York  
Page: https://fireround.dev/companies/nilo

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-10-08 | Series A | $101M | DCVC Bio, Lux Capital, The Column Group | Alexandria Venture Investments, Gates Foundation | [globenewswire.com](https://www.globenewswire.com/news-release/2025/10/08/3163197/0/en/nilo-therapeutics-launches-with-101-million-series-a-financing-to-advance-a-new-class-of-medicines-targeting-neural-circuits-in-immune-disease-and-appoints-kim-seth-as-chief-execut.html), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/immunology-biotech-nilo-launches-101m-and-mission-harness-neural-circuits), [biopharmadive.com](https://www.biopharmadive.com/news/nilo-launch-biotech-column-brain-immune-lux-gates-zuker/802339) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.